Antibody Technology Companies 2010

Publisher: La Merie Publishing
Pages: 283
Format: PDF
Product Line:
LMP Full Report
Product Code: LMFR0003
Release Date: November of 2010

995.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Antibody Technology Companies 2010 – A systematic guide through the landscape of antibody technologies and their providers

The report “Antibody Technology Companies 2010 – A systematic guide through the landscape of antibody technologies and their providers” provides a description and assessment of antibody technologies and their corporate providers as of November 2010. The report describes and analyzes the market size of therapeutic monoclonal antibodies and Fc-fusion proteins in 2009. Characteristics of approved antibody-based products regarding identification, construction and manufacturing are evaluated as a basis for relevant antibody technologies in 2010. Systematic profiles of 96 companies engaged in antibody technologies serve as the basis to present in a structured manner four clusters of platform technologies (generation, optimization, novel constructs, expression/manufacturing). The report serves as a systematic guide through the landscape of companies with antibody technologies for those in search of service providers or partners for collaboration or licensing.

Background

As of October 2010, 34 original therapeutic monoclonal antibodies and Fc-fusion proteins are marketed with 2009 sales exceeding US$ 45.4 bln. Thus, antibodies as a therapeutic modality and technology have matured and availability of new technologies as well as patent expirations offer a multitude of new options when designing an antibody-based product. While the established providers of transgenic mice have been acquired by Big Pharma/Biotech, a plethora of new antibody technologies appeared. Although this landscape of technologies for antibody lead generation and optimization, creation of combinatorial biologics and for expression/manufacturing offers an unprecedented range of possibilities, the selection of the most robust and adequate technologies fitting fitting to the product target profile has become more difficult than ever.

Scope of the report

  • Antibody market 2009
  • Technology analysis of 37 approved therapeutic antibody-based products
  • Profiles of 96 antibody technology companies
  • Antibody technology assessment
  • Antibody pipelines of technology companies
  • Overview of landscape of antibody technologies
  • Guide to identify suitable technologies and providers

Index

  • Overview
  • Market Size of Therapeutic Monoclonal Antibodies and Fc-Fusion Proteins in 2009
  • Characteristics of Approved Therapeutic Monoclonal Antibodies and Fc-Fusion Proteins
  • Platform Technologies for the Generation of Novel Therapeutic Antibody-based Products
  • Platform Technologies for the Optimization of Novel Therapeutic Antibody-based Products
  • Platform Technologies for Products beyond Monoclonal Antibodies
  • Platform Technologies for the Expression and Manufacturing of Novel Therapeutic Antibodies and Antibody-based Products

Companies profiled in the report

  • 4-Antibody
  • Abcheck
  • Abeome
  • Ablexis
  • Ablynx
  • AdAlta
  • Adimab
  • Affimed Therapeutics
  • Affitech
  • Alder Biopharmaceuticals
  • Alligator Biosciences
  • Ambrx
  • AnaptysBio
  • Antitope
  • arGEN-X
  • Armagen Technologies
  • Avanir Pharmaceuticals
  • Avipep
  • BioAtla
  • BioInvent
  • Biolex Therapeutics
  • Biosite
  • Biotecnol
  • Bristol-Myers Squibb (Medarex)
  • Calmune
  • Cephalon (Arana Therapeutics)
  • Chiome Bioscience
  • Crescendo Biologics
  • CytomX
  • Cytos
  • Discerna
  • Dyax
  • Elusys Therapeutics
  • Emergent Biosolutions (Trubion Pharmaceuticals)Epitomics & Apexigen
  • Epivax
  • Esbatech & Delenex
  • Evec
  • ExcelImmune
  • f-star
  • Ganymed Pharmaceuticals
  • Genexine
  • Genmab
  • GlaxoSmithKline (Domantis)
  • Glycotope
  • GTC Biotherapeutics
  • Immunocellular Therapeutics
  • Immunogen
  • InNexus
  • InterVexion Therapeutics
  • Johnson & Johnson (Crucell)
  • Kalo Bios
  • Kenta Biotech
  • Kolltan
  • Kyowa Hakko Kirin (BioWa)
  • Lonza
  • MabCure
  • Macrogenics
  • MAT Biopharma
  • Merck & Co (GlycoFi)
  • Merrimack Pharmaceuticals
  • Merus
  • Micromet
  • Millegen
  • Morphosys
  • Morphotek
  • MSM Protein Technologies
  • Nascent Biologics
  • Neurimmune
  • North Coast Biologics
  • Open Monoclonal Technology (OMT)
  • OriGene Technologies
  • Oxford Biotherapeutics
  • Patrys
  • Pepscan Therapeutics
  • Pfizer (CovX)
  • Philogen
  • Planet Biotechnology
  • Regeneron
  • Sea Lane Biotechnologies
  • Seattle Genetics
  • Sloning Biotechnology
  • Sorrento Therapeutics
  • Symphogen
  • Synageva
  • Syntarga
  • Theraclone
  • Trellis
  • TRION Pharma
  • Vaccinex
  • Vivalis
  • Viventia Biotechnologies
  • XBiotech
  • Xencor
  • XOMA
  • Xori

Sample Pages: Antibody Technology Companies 2010


The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top